Abbott Laboratories
ABT
$133.58
-$0.36-0.27%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 42.34B | 41.95B | 41.22B | 40.73B | 40.33B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.34B | 41.95B | 41.22B | 40.73B | 40.33B |
| Cost of Revenue | 18.65B | 18.66B | 18.19B | 18.09B | 18.05B |
| Gross Profit | 23.70B | 23.30B | 23.03B | 22.63B | 22.28B |
| SG&A Expenses | 11.19B | 11.11B | 10.91B | 10.75B | 10.57B |
| Depreciation & Amortization | 1.83B | 1.88B | 1.89B | 1.92B | 1.95B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.51B | 34.47B | 33.63B | 33.37B | 33.22B |
| Operating Income | 7.84B | 7.48B | 7.58B | 7.36B | 7.11B |
| Income Before Tax | 7.36B | 7.01B | 6.78B | 6.51B | 6.54B |
| Income Tax Expenses | -6.15B | -6.39B | 1.01B | 952.00M | 908.00M |
| Earnings from Continuing Operations | 13.50K | 13.40K | 5.77K | 5.56K | 5.63K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.50B | 13.40B | 5.77B | 5.56B | 5.63B |
| EBIT | 7.84B | 7.48B | 7.58B | 7.36B | 7.11B |
| EBITDA | 11.00B | 10.70B | 10.81B | 10.61B | 10.35B |
| EPS Basic | 7.71 | 7.65 | 3.29 | 3.17 | 3.21 |
| Normalized Basic EPS | 2.68 | 2.54 | 2.59 | 2.50 | 2.43 |
| EPS Diluted | 7.70 | 7.64 | 3.29 | 3.17 | 3.21 |
| Normalized Diluted EPS | 2.67 | 2.54 | 2.59 | 2.49 | 2.42 |
| Average Basic Shares Outstanding | 6.98B | 6.98B | 6.98B | 6.98B | 6.98B |
| Average Diluted Shares Outstanding | 6.99B | 6.99B | 7.00B | 7.00B | 7.00B |
| Dividend Per Share | 2.28 | 2.24 | 2.20 | 2.16 | 2.12 |
| Payout Ratio | 28.92% | 28.62% | 65.30% | 66.47% | 64.35% |